Ascendis Pharma A/S (ASND)Healthcare | Biotechnology | Hellerup, Denmark | NasdaqGS
244.48 USD
+1.53
(0.630%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 244.48 Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ★★☆☆☆ |
Hot Take | April 18, 2026, 10:11 p.m. EDT
ASND is showing strong technical momentum with prices trading above key moving averages, driven by positive Phase 2 trial data (InsiGHTS). The options market is aggressively hedging for higher prices, pushing 260-270 strikes. With a strong forward P/E and consistent revenue growth, secular fundamental downside is low, rewarding the patient capital willing to wait for the next catalyst. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.047447 |
| AutoETS | 0.048775 |
| AutoARIMA | 0.048776 |
| MSTL | 0.049752 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 65% |
| H-stat | 1.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.556 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 11.882 |
| Market Cap | 15,009,398,784 |
| Forward P/E | 20.02 |
| Beta | 0.49 |
| Profit Margins | -31.67% |
| Website | https://ascendispharma.com |
As of April 18, 2026, 10:11 p.m. EDT: Heavy bullish positioning dominates near-term expirations (May/June), evidenced by significant volume spikes in ATM and OTM calls at strikes 240 and 260-270. The Call OTM/OI ratio remains skewed significantly towards the upside (0.67 in May), while Put activity is sparse, showing low volume at protective strikes (220-240) relative to call aggression. Implied volatility is elevated and generally neutral across the board, suggesting jedging markets for sequential upside without significant tail-risk hedging via deep OTM calls.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5170959 |
| Address1 | Tuborg Boulevard 12 |
| All Time High | 250.74 |
| All Time Low | 11.92 |
| Ask | 246.54 |
| Ask Size | 4 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 636,110 |
| Average Daily Volume3 Month | 668,304 |
| Average Volume | 668,304 |
| Average Volume10Days | 636,110 |
| Beta | 0.485 |
| Bid | 242.49 |
| Bid Size | 4 |
| Book Value | -3.1300359 |
| City | Hellerup |
| Compensation As Of Epoch Date | 1,640,908,800 |
| Country | Denmark |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 244.48 |
| Current Ratio | 1.037 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 245.57 |
| Day Low | 241.64 |
| Earnings Call Timestamp End | 1,770,845,400 |
| Earnings Call Timestamp Start | 1,770,845,400 |
| Earnings Timestamp | 1,770,843,600 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | -131,415,000 |
| Ebitda Margins | -0.18249 |
| Enterprise To Ebitda | -116.136 |
| Enterprise To Revenue | 21.193 |
| Enterprise Value | 15,262,003,200 |
| Eps Current Year | 4.416 |
| Eps Forward | 12.211235 |
| Eps Trailing Twelve Months | -4.45 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 229.7773 |
| Fifty Day Average Change | 14.702698 |
| Fifty Day Average Change Percent | 0.063986726 |
| Fifty Two Week Change Percent | 51.70959 |
| Fifty Two Week High | 250.74 |
| Fifty Two Week High Change | -6.26001 |
| Fifty Two Week High Change Percent | -0.02496614 |
| Fifty Two Week Low | 150.89 |
| Fifty Two Week Low Change | 93.59 |
| Fifty Two Week Low Change Percent | 0.62025315 |
| Fifty Two Week Range | 150.89 - 250.74 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,422,455,400,000 |
| Float Shares | 60,917,504 |
| Forward Eps | 12.211235 |
| Forward P E | 20.020906 |
| Free Cashflow | 164,714,256 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,189 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.8682 |
| Gross Profits | 625,217,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00818 |
| Held Percent Institutions | 1.07784 |
| Implied Shares Outstanding | 61,393,156 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. |
| Long Name | Ascendis Pharma A/S |
| Market | us_market |
| Market Cap | 15,009,398,784 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_39510693 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -228,034,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 15,009,398,778 |
| Number Of Analyst Opinions | 16 |
| Open | 244.56 |
| Operating Cashflow | 53,897,000 |
| Operating Margins | 0.009649999 |
| Payout Ratio | 0.0 |
| Phone | 45 70 22 22 44 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 244.48 |
| Post Market Time | 1,776,464,471 |
| Previous Close | 242.95 |
| Price Eps Current Year | 55.36232 |
| Price Hint | 2 |
| Price To Book | -78.10773 |
| Price To Sales Trailing12 Months | 20.842567 |
| Profit Margins | -0.31666002 |
| Quick Ratio | 0.724 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1875 |
| Region | US |
| Regular Market Change | 1.53 |
| Regular Market Change Percent | 0.629759 |
| Regular Market Day High | 245.57 |
| Regular Market Day Low | 241.64 |
| Regular Market Day Range | 241.64 - 245.57 |
| Regular Market Open | 244.56 |
| Regular Market Previous Close | 242.95 |
| Regular Market Price | 244.48 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 359,228 |
| Return On Assets | -0.06863 |
| Revenue Growth | 0.423 |
| Revenue Per Share | 11.882 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,393,156 |
| Shares Percent Shares Out | 0.0602 |
| Shares Short | 3,695,502 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,871,638 |
| Short Name | Ascendis Pharma A/S |
| Short Percent Of Float | 0.0722 |
| Short Ratio | 6.47 |
| Source Interval | 15 |
| Symbol | ASND |
| Target High Price | 345.81424 |
| Target Low Price | 253.32512 |
| Target Mean Price | 294.97974 |
| Target Median Price | 291.20523 |
| Total Cash | 616,041,024 |
| Total Cash Per Share | 10.036 |
| Total Debt | 871,785,984 |
| Total Revenue | 720,131,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 207.51997 |
| Two Hundred Day Average Change | 36.960022 |
| Two Hundred Day Average Change Percent | 0.17810345 |
| Type Disp | Equity |
| Volume | 359,228 |
| Website | https://ascendispharma.com |
| Zip | 2,900 |